Update from the U.S. Food and Drug Administration (FDA)
Saturday, March 4, 2017: 4:45 PM-6:00 PM
Georgia World Congress Center, Building B, Level 2, Room B206
1.25 CME/CE
Paul A. Greenberger , MD FAAAAI

Learning Objectives:
  1. Recognize recent issues of scientific importance at FDA and their clinical implications
  2. Describe the most recent available data from the LABA safety trials
  3. Recognize issues regarding drug hypersensitivity reactions and their clinical implications
4:45 PM
Year-in-Review: An Update from the U.S. Food and Drug Administration
Badrul A. Chowdhury, MD PhD FAAAAI
5:00 PM
Question & Answer
5:10 PM
Update on Epinephrine Injection Products
Peter R. Starke, MD
5:25 PM
Question & Answer
5:35 PM
Allergy and Prescription Drug Labeling
Miya O. Paterniti, MD
5:50 PM
Question & Answer
See more of: Session